tiprankstipranks
Advertisement

FDEV - ETF AI Analysis

Compare

Top Page

FDEV

Fidelity International Multifactor ETF (FDEV)

Rating:66Neutral
Price Target:
FDEV, the Fidelity International Multifactor ETF, has a solid overall rating, largely supported by high-quality holdings like AstraZeneca, Novartis, and Canadian Natural, which show strong financial performance, positive earnings sentiment, and reasonable valuations that help drive the fund’s quality and return potential. However, some holdings such as Endesa and Engie face neutral or slightly bearish technical signals and overbought conditions, and several positions show signs of potential short-term weakness or valuation concerns, highlighting risks around market timing and sector-specific volatility, especially in energy and utilities.
Positive Factors
Solid Recent Performance
The ETF has shown steady gains so far this year and in recent months, suggesting its strategy has been working in the current market.
Strong Energy and Utility Holdings
Several of the largest positions in energy and utilities have delivered strong results, helping to lift the fund’s overall performance.
Broad International Diversification
The fund spreads its investments across many countries and sectors, which can reduce the impact of problems in any single market or industry.
Negative Factors
Mixed Performance Among Top Holdings
While many leading positions are performing well, at least one major holding has been weak, which can drag on returns.
Relatively Low Technology Exposure
The ETF has only a small allocation to technology stocks, so it may not fully benefit when that sector is strong.
Foreign Market and Currency Risks
Because the fund invests heavily outside the U.S., it is more exposed to foreign economic conditions and currency swings.

FDEV vs. SPDR S&P 500 ETF (SPY)

FDEV Summary

Fidelity International Multifactor ETF (FDEV) tracks the Fidelity International Multifactor Index, investing in a wide mix of companies outside the U.S. across many countries like Japan, the UK, and Canada. It holds well-known names such as Shell and AstraZeneca, and spreads money across sectors including financials, health care, energy, and more. The fund looks for stocks with traits like solid quality and steadier price moves, aiming to give investors broad international diversification and long-term growth potential in one ETF. A key risk is that global stock markets can be volatile, so the value of this ETF can go up and down over time.
How much will it cost me?The Fidelity International Multifactor ETF (Ticker: FDEV) has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for ETFs because it is passively managed, tracking a specific index rather than relying on active stock selection.
What would affect this ETF?FDEV's focus on developed markets outside the U.S. and its exposure to sectors like financials, materials, and utilities could benefit from global economic growth, infrastructure spending, and stable demand for essential services. However, challenges such as rising interest rates, regulatory changes in international markets, or economic slowdowns in key regions could negatively impact its performance. Additionally, sector-specific risks, like fluctuating commodity prices for materials or energy, may influence returns.

FDEV Top 10 Holdings

FDEV is leaning heavily on international utilities and financials, with names like Endesa, Engie, Italgas, and Royal Bank of Canada doing much of the heavy lifting as they’ve been steadily rising and giving the fund a solid defensive backbone. On the flip side, big healthcare players such as AstraZeneca and Roche have been losing steam, while Shell and Canadian Natural have shown mixed energy, recently lagging despite earlier strength. The portfolio is spread across developed markets outside the U.S., so performance is driven by a broad ex‑U.S. mix rather than any single country or tech giant.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Shell (UK)1.62%$4.39M£160.46B15.63%
73
Outperform
AstraZeneca1.57%$4.27M$300.37B37.99%
80
Outperform
Novartis AG1.49%$4.05MCHF233.53B28.16%
80
Outperform
Roche Holding AG1.46%$3.97M$337.33B25.57%
73
Outperform
Endesa SA1.43%$3.90M€41.26B48.80%
63
Neutral
Engie SA1.35%$3.67M€70.12B39.80%
64
Neutral
Quebecor1.22%$3.31MC$15.32B63.28%
75
Outperform
Royal Bank Of Canada1.18%$3.21M$284.00B58.67%
75
Outperform
Canadian Utilities A1.16%$3.16MC$14.29B37.72%
72
Outperform
Canadian Natural1.14%$3.10MC$117.92B26.64%
81
Outperform

FDEV Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
35.84
Positive
100DMA
35.85
Positive
200DMA
34.68
Positive
Market Momentum
MACD
0.06
Negative
RSI
53.83
Neutral
STOCH
73.20
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FDEV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 35.66, equal to the 50-day MA of 35.84, and equal to the 200-day MA of 34.68, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 53.83 is Neutral, neither overbought nor oversold. The STOCH value of 73.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDEV.

FDEV Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$278.15M0.18%
66
Neutral
$922.22M0.29%
61
Neutral
$655.16M0.39%
65
Neutral
$647.46M0.59%
60
Neutral
$516.74M0.65%
64
Neutral
$477.72M0.23%
65
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FDEV
Fidelity International Multifactor ETF
35.92
4.52
14.39%
IDHQ
Invesco S&P International Developed High Quality ETF
TLTD
FlexShares Morningstar Developed Markets ex-US Factor Tilt
FYLD
Cambria Foreign Shareholder Yield ETF
TXUE
Thornburg International Equity ETF
AVSD
Avantis Responsible International Equity ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement